LambdaVision GMP is a biotech startup company focusing on developing the world’s first protein-based artificial retina to help patients who have gone blind due to advanced retinitis pigmentosa and age-related macular degeneration (AMD) regain meaningful sight. Founded in 2009 with its headquarters in Farmington, Connecticut, the company’s artificial retina is one of the technologies under evaluation in the International Space Station.